A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer
Current prognostic gene expression profiles for breast cancer mainly reflect proliferation status and are most useful in ER-positive cancers. Triple-negative breast cancers (TNBCs) are clinically heterogeneous, and prognostic markers and biology-based therapies are needed to better treat this disease. We assembled Affymetrix gene expression data for 579 TNBCs and performed unsupervised analysis to define metagenes that distinguish molecular subsets within TNBC. We used n=394 cases for discovery...
Provenance — who produced it, who reused it
Linked to 39 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Survival analysis across the entire transcriptome identifies bio... 2021 · 1,740 cites
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple... 2013 · 731 cites
- Aerobic glycolysis tunes YAP/TAZ transcriptional activity 2015 · 420 cites
- Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance... 2020 · 363 cites
- Identification of Prognosis-Relevant Subgroups in Patients with... 2013 · 161 cites
- Prognostic microRNA/mRNA signature from the integrated analysis... 2013 · 153 cites
- Cross-species oncogenic signatures of breast cancer in canine ma... 2020 · 115 cites
- FADS1/2 control lipid metabolism and ferroptosis susceptibility... 2024 · 77 cites
- SPHK1 regulates proliferation and survival responses in triple-n... 2014 · 73 cites
30 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently